ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

ImageneBio IncNASDAQ: IMA

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 106.9% from a year ago

Cash & equivalents stood at $76.05M at the end of Q1 FY2026, up 106.9% from a year earlier and up 117.5% from the prior quarter. Over 3 fiscal years it compounded at -16.4% a year.

Context

  • Cash & equivalents amounted to 55.6% of total assets at the end of Q1 FY2026, up 27.5 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +106.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$76.05M+117.5% QoQ
Last fiscal yearDec 2025
$34.97M-11.2% YoY
Year agoMar 2025
$36.76M+106.9% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+106.9%——
1 year-11.2%——
3-year CAGR-16.4%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
34.97M USD
Year-over-year change
-11.2%
4-year CAGR
-37.7%

Cash & Equivalents vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +106.9% is the 2nd highest of 9, against a peer median of -35.0%.
  • Cash & equivalents amounts to 55.6% of total assets for IMA, versus a peer median of 36.5%.
IMA Competitors
Cash & Equivalents for IMA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OVIDOvid Therapeutics Inc.Mar 2026$94.06M USD+345.0%-33.6%41.7%
STTKShattuck Labs, Inc.Mar 2026$90.42M USD+48.5%+4.6%88.5%
IMAImageneBio IncMar 2026$76.05M USD+106.9%-16.4%55.6%
STROSutro Biopharma, Inc.Mar 2026$73.68M USD-30.6%+7.1%30.4%
CNTXContext Therapeutics Inc.Mar 2026$54.53M USD-39.0%+23.0%92.6%
CNTBConnect Biopharma Holdings LimitedDec 2025$38.35M USD-51.0%-21.4%68.4%
KLRSKalaris Therapeutics IncMar 2026$34.43M USD-65.9%+217.7%31.4%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$20.96M USD-31.1%-36.1%19.8%
IFRXInflaRx N.V.Mar 2026€15.01M EUR-68.3%-0.5%30.7%
Peer median (excluding IMA) —-35.0%+2.0%36.5%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents232.22M59.92M119.89M39.39M34.97M
Short-term Investments097.03M55.57M84.99M40.82M
Net Receivables00001.3M
Inventory00000
Other Current Assets629K964K1.15M2.78M63.21M
Total Current Assets236.52M160.01M178.66M127.17M140.29M
Property, Plant & Equipment (Net)8.98M8.46M8.02M4.23M790K
Goodwill00000
Intangible Assets00000
Long-term Investments2.39M0000
Tax Assets00000
Other Non-current Assets03.79M5.41M10.11M11.9M
Total Non-current Assets11.36M12.25M13.43M14.34M12.69M
Total Assets247.88M172.26M192.09M141.51M152.98M
Account Payables2.38M2.09M2.07M897K1.44M
Short-term Debt00000
Tax Payables00000
Deferred Revenue17.1M9.16M000
Other Current Liabilities2.84M5.11M3.4M1.75M7.53M
Total Current Liabilities27.19M21.5M14.21M10.78M11.23M
Long-term Debt00007.02M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)7.68M0000
Other Non-current Liabilities00950K1.06M870K
Total Non-current Liabilities12.81M3.79M8.13M4.8M8.6M
Total Liabilities40M25.29M22.34M15.58M19.84M
Common Stock36K36K48K48K11K
Retained Earnings(145.45M)(214.22M)(282.39M)(331.62M)(230.05M)
Accumulated OCI0(763K)(48K)68K87K
Other Stockholders Equity00000
Minority Interest00000
Total Equity207.88M146.97M169.76M125.93M133.14M
Total Debt6.99M5.69M10.74M7.52M10M
Net Debt(225.23M)(54.23M)(109.16M)(31.87M)(24.97M)

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.